Initial public offerings may slowly be coming back to the biotechnology sector.
Eight biotech companies priced IPOs from July through the end of September, raising $1.1 billion in total, according to data compiled by BioPharma Dive. That compares to four in the second quarter, which brought in about $580 million. (Kenvue, J&J’s consumer division, also completed an IPO in May as part of a spinout.)
A handful of other companies are lining up to test the waters, too, offering a glimpse into what could be a busier fourth quarter. Three biotechs, Lexeo Therapeutics, Abivax and Kairos Pharma, on Friday filed plans to go public.
